Erlotinib- and osimertinib-induced changes in gene expression are well characterized; thus, we compared our results to previously annotated genetic signatures for the transcriptional effects of EGFR inhibition in EGFR-mutant NSCLC cells in different contexts. This evidence concerns the gene EGFR and non-small cell lung carcinoma.